REGENXBIO to Participate in Upcoming Investor Conferences
Fireside chat: Wednesday, March 3, 2021 at
Fireside chat: Tuesday, March 9, 2021 at
Morgan Stanley Virtual Healthcare Corporate Access Day
Date:
Live webcasts of the Raymond James and Barclays fireside chats can be accessed in the Investors section of
About
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV® Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
Contacts:
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com
Investors:
brendan@argotpartners.com
Media:
david.rosen@argotpartners.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301234852.html
SOURCE